• Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference

    Source: Nasdaq GlobeNewswire / 07 Jan 2022 13:07:31   America/Chicago

    NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will provide a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference, taking place January 10 - 13, 2022.

    40th Annual J.P. Morgan Healthcare Conference

    Date: Thursday, January 13th, 2022
      
    Time:9:45am Eastern Time
      
    Webcast:The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com 

    About Immunovant, Inc. 

    Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing IMVT-1401 (batoclimab), a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. 

    Contact:

    Tom Dorney, MS, MBA
    Director, Investor Relations & Strategy
    Immunovant, Inc.
    info@immunovant.com


    Primary Logo

Share on,